A lower dosage strength sirolimus (Rapamune) tablet is now commercially available, according to the drug’s maker, Pfizer Inc., of New York.

Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years and older who have received kidney transplants.

“The new 0.5 mg tablet will help clinicians individual their plan to reach target trough levels,” said Mitchell Henry, MD, Chief of the Division of Transplantation and Deputy Director of the Comprehensive Transplant Center at Ohio State University in Columbus.

Continue Reading

From the June 01, 2010 Issue of Renal and Urology News

Topics:

Transplantation